Literature DB >> 8298793

Characterization of purinoceptors mediating depolarization of rat isolated vagus nerve.

D J Trezise1, I Kennedy, P P Humphrey.   

Abstract

1. As part of a broader study to characterize neuronal purinoceptors, the effects of adenosine 5'-triphosphate (ATP) and a range of ATP analogues were investigated on the extracellularly recorded membrane potential of the rat isolated vagus nerve, using a 'grease-gap' technique. 2. ATP evoked depolarization of the rat vagus nerve. The concentration-effect curve to ATP was not monophasic: at the lower concentrations (1 x 10(-5)-1 x 10(-3) M) the curve was shallow (< 50% of the near maximal response to 5-hydroxytryptamine (5-HT)) whilst at higher concentrations the relationship between concentration and amplitude of depolarization was steeper (> 135% of the response to 5-HT at the highest concentration tested, 1 x 10(-2) M). On washout of the high drug concentrations large after-hyperpolarizations were often observed. 3. alpha,beta-methylene ATP (1 x 10(-6)-3 x 10(-4) M), beta,gamma-methylene ATP (1 x 10(-6)-1 x 10(-3) M), and 5'-adenylylimidodiphosphate (beta,gamma-imido ATP; 1 x 10(-6)-1 x 10(-3) M) were all more potent than ATP and produced large depolarizations of the rat vagus nerve at the highest concentrations tested (> 150% of the response to 5-HT). The overall rank order of potency was alpha,beta-methylene ATP > beta,gamma-methylene ATP = beta,gamma-imido ATP > ATP. 4. In contrast, 2-methylthio ATP (1 x 10(-6)-1 x 10(-3) M) produced relatively small depolarizations (< 100% of the response to 5-HT). As was the case with low concentrations of ATP, the concentration-effect curve to 2-methylthio ATP was very shallow. 5. Adenosine 5'-diphosphate (ADP), adenosine 5'-monophosphate (AMP), adenosine and adenosine 5'-O-(2-thiodiphosphate) (ADP-beta-s; all 1 x 10-6 1 x 10-3M) evoked only small depolarizations of the vagus nerve, amounting to 47 +/- 2.5%, 40.8 +/- 7.8%, 33.7 +/- 3.3% and 62.4 +/- 12.7% of the response to 5-HT, respectively. Uridine 5'-triphosphate (UTP; 1 X 10-6 1 X 10-3M) was inactive.6. The P2 purinoceptor antagonist, suramin (1 x 10-5-M-1 X 10-4 M), antagonized responses to alpha-beta-methylene ATP. The nature of this antagonism was not, however, consistent with simple competitive kinetics between agonist and antagonist. Depolarizations produced by beta,gamma-methylene ATP and beta,gamma-imido ATP were also attenuated by suramin (1 x 10-4 M), but in contrast, suramin had no effect on responses to ADP, 2-methylthio ATP, ADP-beta-S or 5-HT.7. In addition to its antagonist effects, suramin (10-4 M) markedly increased the maximum amplitude of the depolarization produced by ATP.8. It is concluded that a heterogeneous receptor population mediates depolarization of the rat vagus nerve by purine nucleotides. Importantly, the large amplitude depolarizations to alpha,beta-methylene ATP,beta,gamma-methylene ATP and beta,gamma-imido ATP are mediated via receptors that share many characteristics of the classical P2, receptor. In contrast, the relatively small depolarizing effects of ADP, ADP-beta-S and 2-methylthio ATP were suramin-resistant. Although it appears that other purinoceptors are present,these data suggest that the rat vagus nerve may serve as a useful preparation for studying the pharmacology of neuronal P2x receptors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8298793      PMCID: PMC2175797          DOI: 10.1111/j.1476-5381.1993.tb13920.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  28 in total

1.  Characterization of P2x-receptors in rabbit isolated ear artery.

Authors:  S E O'Connor; B E Wood; P Leff
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

2.  Suramin is a slowly-equilibrating but competitive antagonist at P2x-receptors in the rabbit isolated ear artery.

Authors:  P Leff; B E Wood; S E O'Connor
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

Review 3.  P2-purinoceptor antagonists.

Authors:  J S Fedan; S J Lamport
Journal:  Ann N Y Acad Sci       Date:  1990       Impact factor: 5.691

Review 4.  Overview. Purinergic mechanisms.

Authors:  G Burnstock
Journal:  Ann N Y Acad Sci       Date:  1990       Impact factor: 5.691

5.  Suramin: a reversible P2-purinoceptor antagonist in the mouse vas deferens.

Authors:  P M Dunn; A G Blakeley
Journal:  Br J Pharmacol       Date:  1988-02       Impact factor: 8.739

6.  ATP regulates muscarine-sensitive potassium current in dissociated bull-frog primary afferent neurones.

Authors:  T Tokimasa; T Akasu
Journal:  J Physiol       Date:  1990-07       Impact factor: 5.182

7.  The effects of some possible inhibitors of ectonucleotidases on the breakdown and pharmacological effects of ATP in the guinea-pig urinary bladder.

Authors:  S M Hourani; J A Chown
Journal:  Gen Pharmacol       Date:  1989

8.  Suramin antagonizes responses to P2-purinoceptor agonists and purinergic nerve stimulation in the guinea-pig urinary bladder and taenia coli.

Authors:  C H Hoyle; G E Knight; G Burnstock
Journal:  Br J Pharmacol       Date:  1990-03       Impact factor: 8.739

9.  Receptors for ATP in rat sensory neurones: the structure-function relationship for ligands.

Authors:  O A Krishtal; S M Marchenko; A G Obukhov; T M Volkova
Journal:  Br J Pharmacol       Date:  1988-12       Impact factor: 8.739

10.  The actions of adenosine 5'-triphosphate on guinea-pig intracardiac neurones in culture.

Authors:  T G Allen; G Burnstock
Journal:  Br J Pharmacol       Date:  1990-06       Impact factor: 8.739

View more
  13 in total

Review 1.  New insights on P2X purinoceptors.

Authors:  P P Humphrey; G Buell; I Kennedy; B S Khakh; A D Michel; A Surprenant; D J Trezise
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-12       Impact factor: 3.000

2.  P2-purigenic receptors regulate phospholipase C and adenylate cyclase activities in immortalized Schwann cells.

Authors:  L N Berti-Mattera; P L Wilkins; Z Madhun; D Suchovsky
Journal:  Biochem J       Date:  1996-03-01       Impact factor: 3.857

3.  Localization and function of ATP and GABAA receptors expressed by nociceptors and other postnatal sensory neurons in rat.

Authors:  Charalampos Labrakakis; Chi-Kun Tong; Tamily Weissman; Carole Torsney; Amy B MacDermott
Journal:  J Physiol       Date:  2003-03-28       Impact factor: 5.182

Review 4.  Crossing the pain barrier: P2 receptors as targets for novel analgesics.

Authors:  C Kennedy; T S Assis; A J Currie; E G Rowan
Journal:  J Physiol       Date:  2003-09-26       Impact factor: 5.182

5.  The use of antagonists to characterize the receptors mediating depolarization of the rat isolated vagus nerve by alpha, beta-methylene adenosine 5'-triphosphate.

Authors:  D J Trezise; I Kennedy; P P Humphrey
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

6.  Functional consequences of inhibition of nucleotide breakdown in rat vas deferens: a study with Evans blue.

Authors:  R Bültmann; B Driessen; J Gonçalves; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-05       Impact factor: 3.000

7.  High affinity P2x-purinoceptor binding sites for [35S]-adenosine 5'-O-[3-thiotriphosphate] in rat vas deferens membranes.

Authors:  A D Michel; P P Humphrey
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

8.  Blockade of P2X-purinoceptors by trypan blue in rat vas deferens.

Authors:  R Bültmann; M Trendelenburg; K Starke
Journal:  Br J Pharmacol       Date:  1994-10       Impact factor: 8.739

9.  Effects of divalent cations on the potency of ATP and related agonists in the rat isolated vagus nerve: implications for P2 purinoceptor classification.

Authors:  D J Trezise; N J Bell; I Kennedy; P P Humphrey
Journal:  Br J Pharmacol       Date:  1994-10       Impact factor: 8.739

10.  Electrophysiological properties of P2X-purinoceptors in rat superior cervical, nodose and guinea-pig coeliac neurones.

Authors:  B S Khakh; P P Humphrey; A Surprenant
Journal:  J Physiol       Date:  1995-04-15       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.